NCT07221565Enrolling by invitationPhase 1/2
Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT)
ImmuneNet: Quantum-Synaptic Immunotherapy Mapping
Source: ClinicalTrials.gov · Last updated 22 May 2026
Brief summary (registry, in English)
The ImmuneNet study is a Phase I/II clinical trial sponsored by Truway Health, Inc. It will test whether gentle, low-frequency electromagnetic resonance (LF-EMR) can influence how immune cells communicate and synchronize with each other. The goal is to see if this "quantum-synaptic" signaling effect can help stabilize immune activity and reduce the number of autoimmune flare-ups in people living with conditions such as lupus, rheumatoid arthritis, or multiple sclerosis. Participants will receive either an active or a sham (placebo) LF-EMR session three times per week for twelve weeks. Each session is completely non-invasive. Blood samples will be collected to study cytokines (immune-system messenger molecules), gene-expression patterns, and electrical field coherence among immune cells. A machine-learning system will analyze these data to predict inflammation patterns and guide individualized treatment settings. All participant data will be securely recorded and time-stamped to ensure transparency and privacy. The expected outcome of the study is a measurable reduction in autoimmune flare frequency and symptom severity, along with improved understanding of how electromagnetic signaling might safely regulate immune function.
- Status (registry)
- Enrolling by invitation
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 23 Oct 2025
- Start date
- 23 Oct 2025
- Primary completion date
- 23 Oct 2034
- Lead sponsor
- Truway Health, Inc.
- NCT number
- NCT07221565
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 120
- From 23 Oct 2025 to the primary completion date, 23 Oct 2034
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior participation in any electromagnetic or quantum resonance study within the past 6 months.
- Use of biologic or investigational therapy initiated within the previous 3 months.
Other illness
- Active infection, malignancy, or significant hepatic, renal, or cardiovascular disease.
- Known photosensitivity, seizure disorder, or history of uncontrolled epilepsy.
Other
- Presence of an implanted medical or electronic device (e.g., pacemaker, defibrillator, deep brain stimulator).
- Pregnancy or lactation.
- Inability to attend at least 80% of treatment sessions or follow-up visits.
Who the study is looking for
- Male or female participants aged 18-70 years.
- Clinical diagnosis of a systemic autoimmune disorder (e.g., systemic lupus erythematosus, rheumatoid arthritis, or multiple sclerosis) confirmed for at least 12 months.
- Stable disease-modifying therapy or corticosteroid regimen for at least 8 weeks prior to enrollment.
- Willingness to maintain current medication schedule for the duration of the study.
- Ability to provide written informed consent and comply with study procedures.
- Access to stable internet or smartphone connection for digital consent verification and symptom tracking.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Truway Health, Inc. www.truwayhealth.com (401 E 34th Street, S11P, New York, NY 10016) Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.